-
-
Medications for Risk Reduction of Breast Cancer in Women
-
In a large population of Caucasian women participating in the Womens Health Initiative Observational Study, those who used aspirin had a significantly lower risk of melanoma and increased duration of use was associated with incrementally greater protection.
-
The FDA has approved paroxetine for the treatment of hot flashes (vasomotor symptoms) in postmenopausal women.
-
How do we involve patients in decisions about their health care? This study from the Informed Medical Decisions Foundation attempts to answer the question using the results of a survey conducted between 2010 and 2011 with a probability sample from across the United States.
-
-
A case-control study of women in the Nurses Health Study Cohort showed that lower melatonin secretion is independently associated with a higher risk of developing type 2 diabetes. There is a physiologic basis for this finding since melatonin has a role in glucose metabolism and lack of melatonin is associated with increased insulin resistance.
-
-
This small proof-of-concept study suggests that yoga may be helpful in patients with highly symptomatic, long-standing paroxysmal atrial fibrillation.
-
The first in a new class of drugs has been approved by the FDA for the treatment of diabetes mellitus. This new class of drugs decreases the renal threshold for glucose excretion by inhibiting the sodium-glucose co-transporter 2 (SGLT2), thus increasing renal clearance of glucose. Canagliflozin is licensed from Mitsubishi Tanabe Pharma Corporation and marketed by Janssen Pharmaceuticals as Invokana.